Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Sanofi SA EPA:SAN
Today's live share price, quote history, chart & news
|Year to date change||-4.24%|
About Sanofi SA
|Entity name||Report date||Shares held|
Aggregated insiders summary data for the last 6 months.
|Full name||Reported title||Total bought||Total sold||Net transacted|
|Full name||Reported title||Effective date||Amount of shares||Price per share||Total cost|
Sanofi SA earnings reports
|Number of Estimates|
|EPS Surprise Dollar|
|EPS Report Date|
|Fiscal End Date|
|Year Ago % Change|
Sanofi SA income statements
|Cost of Revenue|
|Research & Development|
|Selling General & Admin|
|Other Income Expense Net|
|Net Income Basic|
Sanofi SA balance sheet
|Other Current Assets|
|Short Term Investments|
|Long Term Investments|
|Tangible Assets (Net)|
|Other Current Liabilities|
|Total Current Liabilities|
|Long Term Debt|
|Current Long Term Debt|
Sanofi SA cash flow
|Changes in Receivables|
|Changes in Inventories|
|Investing Activity (other)|
|Total Investing Cash Flows|
|Other Financing Cash Flows|
|Cash Flow Financing|
|Exchange Rate Effect|
Sanofi SA dividends
|Ex date||Payment date||Record date||Declared date||Amount||Description||Frequency|
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is collaborating with Sanofi SA (EPA: SAN) to test Kevzara (arthritis drug) as a potential treatment for COVID-19. In a joint statement on Monday, both companies highlighted that the drug failed to show promising results in patients with mild or moderate symptoms of respiratory disease. Kevzara, the companies added, will now be tested only in the critical cases of COVID-19. As per the company, the ind...
Sanofi (EPA: SAN) released its quarterly financial results on Friday that posted an increase in sales and profit attributed to the Coronavirus pandemic that has so far infected more than 2.7 million people worldwide and has caused over 193,000 deaths. The pharmaceutical company recorded its net sales in the first quarter at £7.87 billion that marked a 6.6% increase at constant exchange rates (CER). At £2.04 billion, its net first-quar...
A healthcare research firm, 3 Axis Advisors, announced on Tuesday that major pharmaceutical companies like Sanofi SA, Pfizer, and GlaxoSmithKline have decided to hike up the U.S. list prices for as many as 200 of their manufactured drugs, with implementation plans already in action. The new prices are likely to be applicable from Wednesday. 3 Axis co-founder, Eric Pachman, further highlighted that the average increase in prices will remain capped...
Sanofi shares are higher Wednesday, after the French pharma firm reported better-than-expected third quarter earnings and raised its full-year outlook.
Sanofi shares move lower as French drugmaker agrees deal to buy biotech business Ablynx, in the second deal for Sanofi in a week.
Sanofi shares are lower Monday, following news it has agreed a deal to buy US blood disorder specialist Biovertiv, for $11.6 billion.
Evening Fed announcement on fiscal policy to play lead role in week’s end
MedImmune’s Yong-Jun Liu to leave Anglo-Swedish drugmaker
Drugmakers step up efforts to replenish pipelines
Company to develop treatment to counter blood-thinning effect of Brilinta
Sanofi and Regeneron’s arthritis drug meets goals in Phase 3 trial